Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 12/20 | 0.57 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.46 |
| ▸ | NNMT | P40261 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13610808 | 0.81 | HCAR3 (0.52) | HCAR3HCAR2NNMT | |
| SCHEMBL28093594 | 0.78 | HCAR3 (0.51) | HCAR3HCAR2NNMT | |
| SCHEMBL22256570 | 0.78 | HCAR3 (0.50) | HCAR3HCAR2NNMTEPHX2NPC1 | |
| SCHEMBL28947899 | 0.76 | HCAR3 (0.53) | HCAR3HCAR2EPHX2NPC1MAPT | |
| SCHEMBL16463469 | 0.76 | PTK2 (0.56) | HCAR3HCAR2EPHX2NPC1MAPT | |
| SCHEMBL186474 | 0.73 | HCAR3 (1.00) | HCAR3HCAR2MAPT | |
| SCHEMBL10293002 | 0.72 | HDAC3 (0.54) | HCAR3RAB9ASMN1; SMN2 | |
| SCHEMBL31661260 | 0.72 | HCAR3 (0.69) | HCAR3HCAR2NNMT | |
| SCHEMBL13623668 | 0.72 | MAPT (0.44) | HCAR3NNMTNPC1MAPTRAB9A | |
| SCHEMBL22047713 | 0.71 | HCAR3 (1.00) | HCAR3HCAR2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | ADCYAP1R1, VIPR2, ADCY2 | HCAR3 123/4885HCAR2 58/4885NNMT 2148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.